View metadata, citation and similar papers at core.ac.uk brought to you by CORE
provided by Queen Mary Research Online
Cannabinoids for the control of experimental multiple sclerosis Pryce, Gareth
The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
For additional information about this publication click this link. https://qmro.qmul.ac.uk/jspui/handle/123456789/673
Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] 1 Cannabinoids for the control of experimental multiple sclerosis
GARETH PRYCE
Neuroimmunology Unit, Neuroscience & Trauma Barts and the London School of Medicine and Dentistry Queen Mary University of London
UK 2 This thesis is dedicated in memory of my Dad, Glyn Pryce (1927-2010), with love and thanks.
3 ACKNOWLEDGEMENTS I would like to thank David Baker and Gavin Giovannoni for their supervision and providing me with the opportunity to undertake this thesis. I would like to thank J.Ludovic Croxford, Sam Jackson, Sarah Al Izki from the lab past and present; Ana Cabranes (RIP) and the Javier Fernadez Ruiz laboratory in Madrid, Spain; the Vincenzo Di Marzio Laboratory Naples, Italy; the Andy Irving Laboratory, Dundee; the laboratories of Elga De Vries and Sandra Amor at the Free University Amsterdam, The Netherlands and the laboratories of Ruth Ross and Roger Pertwee in Aberdeen and Alison Hardcastle University College London for providing me with supportive data and particularly Cristina Visintin and David Selwood of University College London and Canbex for providing data from contract Research organizations. I thank Dr. D. Argentieri and Dr. D Ritchie for providing access to RWJ compounds and Dr. M. Ferrari for providing CT3. David Selwood and Cristina Visintin are thanked for supply of VSN16. Jonathan Long and Ben Cravatt are thanked for providing JZL184. Catherine Ledent, Sarah A. Thomas, Beat Lutz, Giovanni Marsicano and Benjamin Cravatt are thanked for supply of mice and materials. I would also like to thank The Multiple Sclerosis Society of Great Britain and Northern Ireland, the National Multiple Sclerosis Society, USA, Aims2Cure; the Brain Research Trust; the Bloomsbury Bioseed Fund; The Wellcome Trust, Canbex and the Pharmaceutical Industry and Barts and the London School of Medicine and Dentistry for support of various aspects of research. I acknowledge RW Johnson, Raritan, New Jersey, USA in part funded experiments involving RWJ compounds. Altantic Ventures part funded some of the early CT3 studies. I am also indebted to the National Institute for Drug Abuse chemical supply programme for donating chemicals for this study. Lastly, but certainly not least I would like to thank my Mum, Dad, my sister Jan and my partner Karen for their support and encouragement. I would particularly like to thank David Baker for his unswerving friendship, support, help, encouragement and cajoling when needed. It has been incredibly rewarding from an intellectual and personal level to work with him for the last thirteen years and hopefully for many more to come. My very great thanks to all!
4
ABSTRACT There have been numerous studies reporting that cannabinoids, both exogenous and endogenous, have a potential beneficial function during incidences of neurological damage. Using gene knockout mice and cannabinoid